Hepatocellular carcinoma remains one of the most common malignant tumors in the world.
Introduction
Hepatocellular carcinoma (HCC or malignant hepatoma) is a primary cancer of the liver and the most common cause of cancer mortality after gastric carcinoma and esophageal carcinoma (1, 2) . Unfortunately, traditional surgery treatments show little efficacy in patients with advanced stage, because only 10-20% of patients with hepatocellular carcinomas can be cured. If the cancer cannot be completely removed, the patients usually die within 3 to 6 months. Radiotherapy and chemotherapy are also popular therapeutic methods in clinical treatments and are usually costly and have serious side effects.
Oncolytic virus is a promising therapy for cancer treatment, employing nature's own agents to identify and destroy malignant cells (3) . Newcastle disease virus (NDV) is one of the naturally occurring viruses with inherent oncolytic ability and potential for cancer therapy (6, 7, 10) . NDV is a single-strand non-segmented negative-sense RNA virus belonging to the Paramyxoviridae family. The genome and BHK-21 were grown in DMEM (GIBCO) with 10% heat-inactivated fetal bovine serum (FBS), 100 μg/ml streptomycin, and 100 μg/ml penicillin. All cell lines were incubated at 37C in an atmosphere of 5% CO 2 .
Plasmids and Virus
The mesogenic NDV Anhinga strain was used to provide a backbone for construction of the recombinant virus. The plasmids pAnh-wt, pTM-N, pTM-P, and pTM-L were kept in our lab and have been described by Estevez et al. (16) . To generate the NDV Anhinga strain expressing enhanced green fluorescent protein (EGFP), the fragment of EGFP was subcloned from pEGFP-C1 (Clontech) into BstB I site between the HN and L genes in pAnh-wt as diagramed in Figure 1 . The recombinant plasmid encoding anti-genome of the NDV Anhinga strain and EGFP gene was named pAnh-EGFP.
Rescue of Recombinant Viruses NDV/Anh-EGFP
The recombinant NDV viruses were rescued as described by Peeters et al. with little modifications. BHK-21 cell monolayers in six-well format were cotransfected with plasmids pAnh-EGFP, pTM-N, pTM-P, and pTM-L (1, 0.5, 0.25, and 0.1 μg respectively) by Lipofectamine 2000 reagent, following the instructive procedures of invitrogen. Before transfection, BHK-21 cell layers were washed once with phosphate buffered saline (PBS) solution and cultivated with 1 ml of Opti-MEM medium (Invitrogen). The transfection reaction was prepared in 500 μl aliquots containing the four plasmids and 6 μl of Lipofectamine 2000. These transfection reagents were added to the cell monolayers. The transfected cells were cultivated in a CO 2 incubator at 37C for 6 h. After incubation the supernatants were removed and substituted with DMEM medium. The six-well format plate was frozen at 280C and thawed in room temperature for three times after cultivation for 72 h in the incubator. The supernatant was harvested and clarified by low-speed centrifugation (2000 g), and 200 μl were used to inoculate 10-day-old pathogen-free egg embryos. The allantoic fluid was harvested for assessment of Figure 1 : Construction of the NDV/Anh-EGFP virus. This picture displays the genome of recombinant NDV/Anh-EGFP virus. EGFP gene fragment was inserted into the BstB I site between HN and L genes of plasmid pAnh-wt. The gene start and gene end sequences were introduced before the ORF of the EGFP gene by PCR. contains 15186 nucleotides coding for six viral proteins in the order 3'-NP-P-M-F-HN-L-5' separated by non-transcribed intergenic (IG) sequences named gene-end (GE), IG and gene-start (GS) (4) . NDV causes severe illnesses in avian, but only mild flu-like symptoms in humans (5) . The virus specifically replicates in cancer cells rather than in normal cells because of the defective interferon (IFN) signal pathways in cancer cells (6) (7) (8) (9) .
The oncolytic ability of NDV was first noticed in 1965 (11) . Since then NDV became a potential candidate for anticancer therapeutics. Several NDV strains including lytic and nonlytic strains have been applied in clinical studies for more than 50 years. Various clinical investigations have proved that NDV is an effective oncolytic agent with no significant acute or chronic side effects (12) . In 1999, Peeters et al. (13) and Römer-Oberdörfer et al. (14) successfully rescued NDV by reserves genetics, which provided a technology for exploring and developing NDV with stronger oncolytic capability. Vigil et al. (6) demonstrated that using reverse genetics could enhance the oncolytic property of NDV by expressing highly fusogenic F protein, murine granulocyte macrophage colony stimulating factor (GM-CSF), interferon-γ (IFN-γ), interleukin-2 (IL-2) or tumor necrosis factor-α (TNF-α). Zhao et al. (15) proved that recombinant NDV expressing IL-2 possessed a strong cytolytic activity in various human cell lines. Different NDV strains have different effects on tumor therapy, so it is important and significant to discover more effective oncolytic NDV virus. The Anhinga strain has not been studied with respect to its potential as an anti-hepatoma therapeutic NDV strain. Therefore, we analyzed the oncolytic ability of NDV Anhinga strain on hepatocarcinoma in vitro and in vivo. To facilitate monitoring, the EGFP protein was engineered into NDV. We concluded that NDV Anhinga strain is likely classified as a lytic strain.
Further results revealed that the NDV Anhinga strain could become a new potent candidate for clinical carcinoma therapy especially for hepatocarcinoma and established a platform for optimizing and reconstructing the strain for tumor therapy in the future. 
Materials and Methods

Cell Lines and Culture
EGFP Expression
Cells in six-well plates were infected with recombinant viruses at multiplicities of infection (MOI) of 0.01, 0.1, and 1.0. The inoculums were removed 6 h post-incubation. The cells were photographed at 48, 72, and 96 h post-infection by fluorescence microscope (Nikon, TS100).
In vitro Virus Growth in HepG2 Cells
Viral growth was determined in the HepG2 cell line. Cells planted in 24-well plates were infected with recombinant virus at MOI of 10. The supernatants were collected at 24, 48, 72, and 96 h post-infection. The viral concentration was measured by end-point titration on DF-1 cells and calculated as 50% tissue culture infective dose (log 10 TCID 50 ) per ml.
In vitro Inhibition Assay
The cytotoxicity of NDV/Anh-EGFP was evaluated in HepG2 cell line. 1  10 5 cells were plated per well in a 96-well plate and incubated with virus at MOI of 0.01, 0.1, 1, 10, and 100 for 1 h. After 72 h the virus was removed, then washed with PBS and cell culture fluid (contain 5% serum) was added to the plate. 50 μl MTT solution (5 mg/ml) was added for each well at 24, 48, and 72 h. After 4 h incubation, 200 μl DMSO was added per well, the plates were vibrated for 10 min, all samples were analyzed in triplicate. A spectrophotometer was used to determine the optical density (OD) at the absorbance of 570 nm. The survival ratio was calculated using the formula:
Survival ratio 5
Average OD value of treated group  100%. Average OD value of contrast group
Animal Studies
All procedures involving animals followed the guidelines issued by National Institute of Health and the Institutional Animal Care and Use Committee of Northeast Agriculture University. Six-week-old Kunming mice were housed in a pathogen-free environment and implanted subcutaneously with 5  10 5 H22 cells. Tumor volume was measured every other day using a digital caliper in two dimensions. Tumor volume was calculated using the formula:
where V is the tumor volume, S is the smaller measured diameter, and L is the larger diameter (6) . When tumor size reached 58 mm in diameter (812 days), mice were intratumorally injected with 10 7 pfu of NDV/Anh-EGFP (200 μl) viruses or phosphate buffered saline (PBS) (200 μl) every other day for a total of four injections. Animals were sacrificed when tumor size reached 18 mm in any dimension or at the termination of the experiment.
Results
Generation of the Recombinant Virus NDV/Anh-EGFP
The EGFP gene ORF with gene start and gene end sequences was sub-cloned at BstB I restriction enzyme site between HN and L genes (Figure 1 ). The recombinant virus was generated by cotransfection of the plasmid coding for the virus anti-genome with NP, P, and L. Cell fusion and fluorescence could be first observed at 48 h post-transfection, which provided evidence of virus production. The viral population was amplified by inoculation of the cell cultures into 10-day-old SPF embryonated chicken eggs. Allantoic fluid was collected at 72 h after infection for hemagglutination (HA) and TCID 50 tests. The HA titer reached 1:128 and the TCID 50 titer was 2  10 8 (data not shown).
Growth Characteristics of the Recombinant Virus
To analyze the growth characteristics of the recombinant virus NDV/Anh-EGFP in HepG2 cell line, NDV/Anh strain rescued without foreign gene was used as a control. HepG2 cells in 24-cell plate were infected with recombinant virus at 37C in DMEM with 10% fetal calf serum (FCS) in 5% CO 2 incubator. The supernatant was harvested at the time 0, 24, 48, 72, and 96 h post-infections. The TCID 50 was calculated by plating (Figure 2 ), there is no significant difference between the growth kinetics of the two viruses. The viral yield of NDV/ Anh-EGFP was slightly lower than that of NDV/Anh.
EGFP In vitro Expression
To observe the viral infection and EGFP protein expression in hepatoma cell line, EGFP was monitored on 24, 48, 72, and 96 h after viral inoculation at MOI of 10 by fluorescence microscopy. HepG2 cells were completely infected on 72 h and syncytia could be observed (Figure 3) .
In vitro Inhibition Assay
The tumor growth inhibitory ability of NDV/Anh-EGFP was detected on HepG2 cells at MOI of 0.01, 0.1, and 10. The viability of the HepG2 cell was detected by MTT at 24, 48, and 72 h. The viability was over 69.8% at the lowest MOI of 0.01 and at the MOI of 10 the viability was only 23.45%. The variation of viability presented as does dependent (Figure 4 ).
In vivo Treatment of Hepatoma with NDV/Anh-EGFP
To evaluate the in vivo inhibitory efficacy of NDV/Anh-EGFP as an oncolytic agent, 10 5 H22 cells were s.c. implanted in the right inguen. Tumors developed for 812 days, a palpable tumor was formed. When tumors volume reached 50100 mm 3 , mice were intratumorally (i.t.) injected with 10 7 pfu virus every other day for a total of four times and with PBS for control. NDV/Anh-EGFP virus exhibited obvious inhibitory efficacy compared with PBS. In 2 out of 5 mice treated with NDV/Anh-EGFP underwent complete regression between 23 weeks after the first injection. Two way ANOVA analyses revealed that there are no interactions between time and drug treatment. In the second day, the average volume of PBS group and drug treatment group is 208.76 and 148.75 mm 3 ; In the fourth day, the average volume of PBS group and drug treatment group is 462.24 and 205.91 mm 3 ; With no consideration of time factor, there is significant difference in tumor volume growth between PBS group and NDV/ Anh-EGFP treated group on the second and fourth day (P  0.05). The result elucidated that NDV/Anh-EGFP strain could effective suppress the tumor growth, especially in the early stage.
More importantly, the two mice which had undergone complete tumor regression exhibited a persistent protection when rechallenged with 10 5 H22 cell (the same tumor cells they bore before, in opposite inguen, 60 days after complete regression) ( Figure 5 ).
Discussion
Newcastle disease virus has been applied in clinical studies of cancer for more than half a century. NDV could specifically infect and kill tumor cells causing only mild side effect in humans, making it an attractive candidate of oncolytic agent. Many naturally-occurring NDV strains have been extensively studied in pre-clinical and clinical trials for its oncolytic ability. One of the most interesting results appeared in Dr. William Cassel's research in which he treated patients with stage III malignant melanoma with NDV-oncolysates 73-T strain. A strain classified as a mesogenic virus and regarded as the most potently oncolytic agent of the NDV strains (18, 19) . During a span of 20 years, Cassel's research showed that 63% of 81 patients became tumor-free after 10 years (20) . In a 10 year follow-up on stage II malignant melanoma in which patients were treated post-surgically with NDV oncolysate, 44% survived over 20 years. In 1996, live attenuated NDV MTH-68/H strain was administered i.v. to 14 stage IV glioblastoma multiform patients. In these patients, five died from cancer, two others died due to other reasons and another seven patients who had been i.v. treated NDV MTH-68/H strain as the only therapeutics lived for 5-9 years (21) .
NDV could be classified as lytic strains and non-lytic strains, based on the different oncolytic capabilities. Lytic strain usually includes 73-T (22), MTH-68/H (23) , and PV 701 (24) can kill the tumor cells directly and prevent metastasis by specifically inducing cells fusion to form syncytia (25) . Nonlytic strains (e.g., Ulster strain) (25, 26) can gradually induce tumor regression by affecting the metabolism of the host cell 31 and enhance the immune response in vivo (25) . In our study, we demonstrated that the treatment of tumor bearing mice with the NDV/Anh-EGFP strain IT led to tumor regression. Most of the tumor cells were induced to form syncytia; therefore the NDV Anhinga strain is likely a lytic strain.
Cancer remains a major cause of death in humans. However, the present therapeutics has not much improved the survival rate of the patients especially with metastases. In addition to the limitation of resection and side effects of chemo-and radiotherapy, it is necessary to develop new systematic treatments for cancer therapy. Hepatocellular carcinoma is the third common cause of cancer-related death worldwide (1, 27) . More than 75% of cases occur in the Asia-Pacific region and more than 50% of hepatocellular carcinoma occurs in China alone (28, 29) . It was estimated that 360,000 patients residing in East Asian countries, including China, Japan, Korea, and Taiwan, die from this cancer each year (1, 27) . Unfortunately most symptoms when diagnosed are already in the mediate or advanced stages, therefore surgical resection could only be applied to less than 20% of patients (30) . Despite wide and aggressive usage of chemo-and radiation therapy in clinical treatments, the overall survival rates of metastasizing cancer patients, which is the most common phenomenon in clinic, have not been significantly improved in the past decades. In addition, the severe side effects present doubt regarding the usefulness of conventional therapeutics.
The potency against micro metastases and prevention of development of peritoneal disease by oncolytic NDV has already been studied. In Song et al. (31) research, peritoneally disseminated gastric cancer mice were completely cured by treatment with the recombinant NDV. Our study demonstrated that NDV/Anh-EGFP is efficacious in hepatocellular carcinoma model, especially in the early stage, and has the potency to cure the mice completely. Thereby we offered a new candidate for Hepatocellular micrometastases treatment. Vigil et al. (10) reported that lytic strain virus could not only kill the tumor directly, but could also elicit a potent immunological memory in therapeutic process, which has been proved by non-lytic strain virus. Vigil et al. used NDV Hitchner B1 (B1 strain) lentogenic strain as a backbone to construct recombinant virus NDV/F3aa which contain a multibasic cleavage site in the F protein of the virus. The NDV/ F3aa strain has an increased antitumor efficacy compared with the wild-type parental NDV (B1 strain) by increasing the fusion capability of tumor cell membrane. Then using NDV/F3aa strain as backbone, they inserted the IL-2 and minigal gene separately to construct the NDV/F3aa-minigal and NDV/F3aa-IL-2 strains. Finally, they evaluated the therapeutic efficacy of the two recombinant viruses on immune competent CT26.CL25 BALB/c mice model. The result revealed that co-treatment with NDV/F3aa-minigal and NDV/F3aa-IL-2 led to 9 out of 10 mice undergoing complete regressions. The mice that had complete tumor regressions were protected when rechallenged on the contralateral flank 60 days post-tumor treatment initiated with the cell which the mice have been inoculated before. In our study, 60 days post-treatment, mice which were completely cured by previous therapy were also well protected when rechallenged with the same tumor cell. We also observed that animals experienced with multiple injections didn't show any behavioral changes nor any malformations or carcinogenesis signs in their descendants.
In conclusion, this study demonstrates NDV Anhinga strain could specifically lead the tumor regression in vitro and in vivo thereby providing a new candidate for cancer therapy. Using reverse genetics to construct NDV Anhinga strain to express EGFP not only provided a biological marker, but also built up a technical platform for integration of other cytokines in order to enhance the potency of tumor therapy. Further studies remain necessary to improve the Anhinga strain as an oncolytic agent against Hepatocellular carcinoma in clinical application.
